image credit: Unsplash

Drugmakers flock to Vineti’s fix for a cell, gene therapy problem

March 24, 2021

The cell and gene therapy field hit major milestones over the last few years. In the summer of 2017, the Food and Drug Administration approved a first-of-its-kind cellular medicine from Novartis for a hard-to-treat form of leukemia. Less than two months later, another cell therapy developed by Kite Pharma was cleared for patients with a different blood cancer.

Before the end of that year, Spark Therapeutics received the first-ever FDA nod for a gene therapy targeting an inherited disorder. And since then, a small crop of advanced medicines developed by Kite, Juno Therapeutics and AveXis have come to market.

Read More on Biopharma Dive